78 
Enriching RWE with Novel Data Sets: How Medical Imaging Data Can Accelerate Drug Development
hea!thcare innovation - Clinical IT
MAY 16, 2019
Real-world evidence has the potential to be especially valuable in a number of healthcare use cases
Drug Development Related Topics 
AI Doesn’t Ask Why — But Physicians And Drug Developers Want To Know
Healthcare Guys
NOVEMBER 16, 2018
At long last, we seem to be on the threshold of departing the earliest phases of AI, defined by the always tedious “will AI replace doctors/drug developers/occupation X?” By DAVID SHAYWITZ MD.
Trending Sources
How telemedicine is increasing diversity in clinical trials
KevinMD
MARCH 14, 2019
An important part of advancing medical research and drug development is making participation in clinical trials easier and more inclusive.
Ben-Gurion University introduces AI platform for monitoring and predicting ALS progression
Mobi Health News
FEBRUARY 19, 2019
BenevolentAI gets $115M to harness AI for new drug discovery
Mobi Health News
APRIL 20, 2018
BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States.
Cost of antibiotic-resistant infections in U.S. tops $2B per year
FierceHealthIT
MARCH 22, 2018
The study’s authors urge policymakers to support the development of new strategies to prevent infections and to support innovative antibiotic drug development A new study finds that antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient. Multiply that by the estimated number of antibiotic-resistant infections, and costs run well over $2 billion per year.
|
MedTech’s Role in Fighting the Opioid Epidemic
Duane Boise
JANUARY 24, 2018
Of the 50,000 drug overdose deaths that occurred in 2015, roughly 33,000 of them were caused by opioids. More forms of technology are being developed every day to treat patients suffering from chronic pain, and to remedy those that may be struggling with an opioid addiction.
Blockchain: Its Future in Healthcare is Happening Now
Phoenix Health Systems
JUNE 28, 2018
For physicians, this would enable customized individual treatment plans co-developed by a patient’s various caregivers, based on full histories, patient genetics, lifecycle and environment. Interoperability. Blockchain.
Blockchain in Healthcare: A Vehicle Towards Digital Health 2.0?
The Digital Health Corner
MARCH 26, 2018
Blockchain was first developed as a means of transaction for the digital currency Bitcoin. Blockchain technology’s potential impact on the life sciences industry (drug development, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain. One can envision how blockchain might also stop drug counterfeiting thereby improving patient safety.
Artificial Intelligence in Healthcare: What We Know so Far
Perficient
FEBRUARY 13, 2019
It will also help facilitate drug development. A recent article by Fortune describes how future healthcare practitioners hope to have screened enough people to uncover new biomarkers that can help predict cancer before it develops. The healthcare industry is changing every day; from best practices to technological advancements. The industry is seeing exponential growth in regards to virtual reality, 3D printing, and artificial intelligence.
Lilly Acquires Rights to Nasal Glucagon
Insulin Nation
OCTOBER 16, 2015
has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.
|
|
Leveraging T2D Drugs to improve T1D Therapy
Insulin Nation
NOVEMBER 27, 2018
In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugs developed to treat Type 2 diabetes. This was the first research ( release ) on using this Type 2 approved drug for T1D treatment and there were larger confirmatory studies ( release ) in 2016 and 2018. The study will supplement insulin therapy with these two drugs designed to treat Type 2 Diabetes or with semaglutide alone. “
Novartis CEO Is Going All in With Some Big Bets on R&D
Lloyd Price
NOVEMBER 21, 2018
In an interview with the Wall Street Journal, Narasimhan pointed to some of the investments the company has made into the cutting-edge areas of drug development, such as gene therapy and radiopharmaceuticals.
FemTech: The rise of Female Health innovation
Lloyd Price
JUNE 4, 2018
CVC’s recent acquisition of the women’s health division of the Israeli drug developer Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Silicon Valley Bank, Zinc.vc
Donald Trump and Diabetes Policy: What We Know Right Now
Insulin Nation
NOVEMBER 14, 2016
Within a bullet point about Obamacare is this sentence: “Reforms will also include cutting the red tape at the FDA: there are over 4,000 drugs awaiting approval, and we especially want to speed the approval of life-saving medications.”.
Genomics Startup Human Longevity’s Valuation Falls 80% from $1.6 Billion down to $310M
Lloyd Price
DECEMBER 8, 2018
But key facets of its business didn’t develop as planned, say people familiar with the company. It had hoped to sell analytics to pharmaceutical companies as they increasingly incorporated genetic sequencing into drug development, these people say. Human Longevity Inc.
Lilly Acquires Rights to Nasal Glucagon
Insulin Nation
OCTOBER 16, 2015
has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.
How the 21st Century Cures Act Will Change Diabetes Care
Insulin Nation
DECEMBER 14, 2016
This legislation boosts funding to the National Institutes of Health and establishes an innovation grant fund to “accelerate the discovery, development, and delivery” of new treatments and therapies. She also said the bill opened the door to easy off-label use of FDA-cleared drugs. “I
What is Metformin?
Insulin Nation
OCTOBER 10, 2017
A drug prescription can come with a lot of questions. With our “Know Your Drugs” series, we provide you with a snapshot of the different diabetes drugs on the market, and links to additional information.
BCG Vaccine Shows Promising Signals of T1D Efficacy
Insulin Nation
FEBRUARY 7, 2019
We found in human and mouse research that defects in white blood cells causing disease had a signaling pathway that we could drug. We looked for generic drugs that stimulate TNF. The Hygiene Hypothesis was developed in the UK in the 1960s.
Join us at the Global Clinical Trials Connect 2018, 25-26 April, London
mHealth Insight
APRIL 24, 2018
“The Global Clinical Trials Connect 2018 conference focuses on introducing pioneer technology, developing better patient engagement and collaborating strategies in clinical trials. Aji Barot, Business Development Director, HealthUnlocked.
Lilly Acquires Rights to Nasal Glucagon
Insulin Nation
OCTOBER 16, 2015
has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.
New Blockchain ledger will let US residents sell personal Healthcare data
Lloyd Price
SEPTEMBER 9, 2018
Most people don't know it but there is a multi-billion dollar industry that collects healthcare information, strips it of basic personal identifiers such as name, address and Social Security Number, and then sells it off to researchers, drug developers, marketers and others.
FDA Gives Diabetes Treatments Low Priority
Insulin Nation
JULY 14, 2015
DiMasi, PhD, who analyzes the economics of health care at the Tufts University Center for the Study of Drug Development. We’ve seen very large trials and lengthening clinical development times, which would suggest larger than average development costs,” DiMasi said.
Path to Better Clinical Trials for T1D Delay/Prevention
Insulin Nation
FEBRUARY 14, 2019
The Critical Path Institute (C-Path) is a catalyst in the development of new approaches including biomarkers and modeling and analysis tools to support clinical trial design and clinical outcome assessments.
Let's personalize your content